VERU INC. - COMMON STO

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

28 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

25 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

10 Jun 2021 05:30:01 By Nasdaq GlobeNewswire

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 05:15:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Virtual Healthcare Conference

25 May 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

24 May 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

19 May 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues

12 May 2021 03:30:00 By Nasdaq GlobeNewswire

Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021

05 May 2021 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th

28 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress

21 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

09 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

08 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

02 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

01 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Submits New Drug Application for Proprietary TADFIN for BPH

23 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

Veru Announces Pricing of Public Offering of Common Stock

17 Feb 2021 18:30:00 By Nasdaq GlobeNewswire

Veru Announces Proposed Public Offering of Common Stock

17 Feb 2021 13:01:00 By Nasdaq GlobeNewswire

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter

10 Feb 2021 03:30:00 By Nasdaq GlobeNewswire